drugset / Trial / NCT04388033
Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.
Phase 1/2
Unknown
10 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
CyTIX.Inc · collabHangzhou Medical Biotechnology Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
A multi-center, open-label, single-arm, phase I/II clinical study is designed to test the safety and immunogenicity of an investigational Dendritic and Glioma Cells Fusion vaccine given with IL-12 for treatment-naïve patients after resection of glioblastoma.
Timeline
- Start
- 2020-12
- Primary completion
- 2022-12
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dendritic Cell/Tumor Fusion Vaccine | Vaccine | — | Other |
| Background | Temozolomide | Small molecule | 150 mg/m2 | — |
| Background | Temozolomide | Small molecule | 200 mg/m2 | — |
| Background | interleukin-12 | Protein / enzyme biologic | 6 ug | Subcutaneous |